James Loerop - Jan 31, 2022 Form 3 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Business Officer
Signature
/s/ Mark Ballantyne, as Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jan 31, 2022
Transactions value $
$0
Form type
3
Date filed
2/1/2022, 03:45 PM
Previous filing
Jul 12, 2021
Next filing
Feb 1, 2022

No securities are beneficially owned.

Remarks:

No securities are beneficially owned. Exhibit 24.1 - Power of Attorney